Clinical Trial

Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei

Name: Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei — clinical trial record (NCT07341360)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Pseudovax

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

Participants will receive vaccination with Pseudovax/GM-CSF in combination with PD-1 inhibitor tislelizumab over a period of up to two years. The vaccine is expected to reactivate measurable immune response, and tislelizumab to restore anticancer immunity in patients with GNAS mutated pseudomyxoma peritonei.

Trial Details

NCT Number	NCT07341360
Lead Sponsor	Oslo University Hospital Collaborators: BeiGene
Conditions	Pseudomyxoma Peritonei
Enrollment	10 participants
Start Date	2025-10-13
Primary Completion	2029-12-31 (estimated)
Study Completion	2034-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-14